As FDA resumes foreign inspections, GAO recommends revamping the program

In a report published Monday, the Government Accountability Office (GAO) raises questions about the US Food and Drug Administration’s (FDA) foreign inspections program for drugs and says the program is long due for an overhaul. The report comes amid the agency’s ongoing challenges in conducting foreign inspections due to the COVID-19 pandemic.